Literature DB >> 10948160

Impaired control of Brucella melitensis infection in Rag1-deficient mice.

M J Izadjoo1, Y Polotsky, M G Mense, A K Bhattacharjee, C M Paranavitana, T L Hadfield, D L Hoover.   

Abstract

After intranasal inoculation, Brucella melitensis chronically infects the mononuclear phagocyte system in BALB/c mice, but it causes no apparent illness. Adaptive immunity, which can be transferred by either T cells or antibody from immune to naive animals, confers resistance to challenge infection. The role of innate, non-B-, non-T-cell-mediated immunity in control of murine brucellosis, however, is unknown. In the present study, we documented that BALB/c and C57BL/6 mice had a similar course of infection after intranasal administration of 16M, validating the usefulness of the model in the latter mouse strain. We then compared the course of infection in Rag1 knockout mice (C57BL/6 background) (referred to here as RAG-1 mice) which have no B or T cells as a consequence of deletion of Rag1 (recombination-activating gene 1), with infection in normal C57BL/6 animals after intranasal administration of B. melitensis 16M. C57BL/6 mice cleared brucellae from their lungs by 8 to 12 weeks and controlled infection in the liver and spleen at a low level. In contrast, RAG-1 mice failed to reduce the number of bacteria in any of these organs. From 1 to 4 weeks after inoculation, the number of splenic bacteria increased from 2 to 4.5 logs and remained at that level. In contrast to the consistently high numbers of brucellae observed in the spleens, the number of bacteria rose in the livers sampled for up to 20 weeks. Immunohistologic examination at 8 weeks after infection disclosed foci of persistent pneumonia and large amounts of Brucella antigen in macrophages in lung, liver, and spleen in RAG-1, but not C57BL/6, mice. These studies indicate that T- and B-cell-independent immunity can control Brucella infection at a high level in the murine spleen, but not in the liver. Immunity mediated by T and/or B cells is required for clearance of bacteria from spleen and lung and for control of bacterial replication in the liver.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948160      PMCID: PMC101794          DOI: 10.1128/IAI.68.9.5314-5320.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice.

Authors:  J A Montaraz; A J Winter
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

Review 2.  The isolation of Brucellae from contaminated sources. A review.

Authors:  L Robertson; I D Farrell; P M Hinchliffe
Journal:  Br Vet J       Date:  1977 Mar-Apr

3.  Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK).

Authors:  D L Hoover; R M Crawford; L L Van De Verg; M J Izadjoo; A K Bhattacharjee; C M Paranavitana; R L Warren; M P Nikolich; T L Hadfield
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Phagocytosis and killing of Brucella by human polymorphonuclear leukocytes.

Authors:  E J Young; M Borchert; F L Kretzer; D M Musher
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

5.  In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection.

Authors:  H Pavlov; M Hogarth; I F McKenzie; C Cheers
Journal:  Cell Immunol       Date:  1982-07-15       Impact factor: 4.868

6.  Comparison of Brucella abortus and Brucella melitensis infections of mice and their effect on acquired cellular resistance.

Authors:  E J Young; C I Gomez; D H Yawn; D M Musher
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

7.  Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.

Authors:  L L Van De Verg; A B Hartman; A K Bhattacharjee; B D Tall; L Yuan; K Sasala; T L Hadfield; W D Zollinger; D L Hoover; R L Warren
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  Induction of immune and adjuvant immunoglobulin G responses in mice by Brucella lipopolysaccharide.

Authors:  E Moreno; R S Kurtz; D T Berman
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

9.  Studies on the immune protection to murine experimental brucellosis conferred by Brucella fractions. I. Positive role of immune serum.

Authors:  S Bascoul; A Cannat; M F Huguet; A Serre
Journal:  Immunology       Date:  1978-08       Impact factor: 7.397

10.  Duration of strain 2308 infection and immunogenicity of Brucella abortus lipopolysaccharide in five strains of mice.

Authors:  M Phillips; G W Pugh; B L Deyoe
Journal:  Am J Vet Res       Date:  1989-03       Impact factor: 1.156

View more
  20 in total

1.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Silvia de la Barrera; Silvia M Estein; Laura Bruno; Raúl Bowden; Karina A Pasquevich; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Course of infection with the emergent pathogen Brucella microti in immunocompromised mice.

Authors:  María P Jiménez de Bagüés; Alba de Martino; Juan F Quintana; Ana Alcaraz; Julián Pardo
Journal:  Infect Immun       Date:  2011-08-08       Impact factor: 3.441

4.  Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine.

Authors:  Apurba K Bhattacharjee; Mina J Izadjoo; Wendell D Zollinger; Mikeljon P Nikolich; David L Hoover
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

5.  CXCR2 Mediates Brucella-Induced Arthritis in Interferon γ-Deficient Mice.

Authors:  Carolyn A Lacey; Lauren L Keleher; William J Mitchell; Charles R Brown; Jerod A Skyberg
Journal:  J Infect Dis       Date:  2016-03-06       Impact factor: 5.226

6.  Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used.

Authors:  Carlos A Velikovsky; Fernando A Goldbaum; Juliana Cassataro; Silvia Estein; Raúl A Bowden; Laura Bruno; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

7.  Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice.

Authors:  Marie-Alice Vitry; Carl De Trez; Stanislas Goriely; Laure Dumoutier; Shizuo Akira; Bernhard Ryffel; Yves Carlier; Jean-Jacques Letesson; Eric Muraille
Journal:  Infect Immun       Date:  2012-09-24       Impact factor: 3.441

8.  Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge.

Authors:  M M Kahl-McDonagh; A M Arenas-Gamboa; T A Ficht
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

9.  Natural antibody contributes to host defense against an attenuated Brucella abortus virB mutant.

Authors:  Hortensia G Rolán; Mariana N Xavier; Renato L Santos; Renée M Tsolis
Journal:  Infect Immun       Date:  2009-04-13       Impact factor: 3.441

10.  A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.

Authors:  Patricia S Doyle; Yuan M Zhou; Juan C Engel; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2007-08-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.